M. Elsalhy et al., COLONIC ENDOCRINE-CELLS IN PATIENTS WITH CARCINOMA OF THE COLON, European journal of gastroenterology & hepatology, 10(6), 1998, pp. 517-522
Objective To investigate the colonic endocrine cells in patients with
colon carcinoma in order to establish a possible abnormality. Patients
Twelve patients with colon adenocarcinoma (eight women and four men;
mean age 69 years; range 52-88 years) were studied, As controls, macro
scopically and histologically normal tissues from the colon of 12 pati
ents (eight women and four men; mean age 66 years; range 34-86 years)
were examined. These patients suffered from polyps, prolapsus, chronic
diverticulitis, volvulus or haemorrhoids. Methods Macroscopically and
histologically normal tissues from the colon of the patients, about 1
0 cm from the tumour, and of the controls were examined. Endocrine cel
ls were immunostained with the avidin-biotin-complex method, and were
quantified by computer image analysis using an automatic standard sequ
ence analysis operation, Three parameters were used: (1) the number of
endocrine cells per mm(3) of epithelial cells; (2) the cell secretory
index (CSI); and (3) the nuclear volume. Results The numbers of somat
ostatin- and serotonin-immunoreactive cells were significantly reduced
in patients with colon carcinoma (P = 0.03 and 0.009, respectively),
There was no difference between patients and controls regarding the nu
mbers of PYY-, PP-, and enteroglucagon-immunoreactive cells. The CSI o
f somatostatin- and serotonin-immunoreactive cells were significantly
decreased. There was no difference in the CSI between the patients and
controls regarding PYY-, PP- or enteroglucagon-immunoreactive cells.
The nuclear volumes of PYY- and enteroglucagon-immunoreactive cells in
creased significantly in the patients, The nuclear volume of PP-, soma
tostatin- and serotonin cells did not differ from those of the control
s. Conclusion The present results support the assumption that a distur
bance in the colonic neuroendocrine system occurs in patients with col
on carcinoma, which might affect the development of the tumour, The de
crease in the number and CSI of somatostatin cells may account for the
decrease of the colonic content of this peptide observed previously i
n these patients, The decrease in the number and CSI of serotonin-immu
noreactive cells in patients with colon adenocarcinoma might be a meth
od by which the body defends itself against this mitogenic substance,
Eur J Gastroenterol Hepatol 10:517-522 (C) 1998 Lippincott-Raven Publi
shers.